Table 1.
Clinical Characteristics, and Endocrine, Metabolic, and Anthropometric Parameters in Male and Female Patients With Acromegaly Preoperatively and 1 Year Postoperatively
| Male Patients (n = 10) |
Preoperative vs Postoperative P Value | Female Patients (n = 13) |
Preoperative vs Postoperative P Value | |||
|---|---|---|---|---|---|---|
| Preoperative | Postoperativea | Preoperative | Postoperativea | |||
| Age, y | 39 ± 13 (18–54) | 48 ± 12 (23–69) | ||||
| Weight, kg | 100.5 ± 11.6 | 101.4 ± 13.8 | .37 | 76.8 ± 15 | 77 ± 15 | .67 |
| Height, cm | 184.2 ± 7.4 | 183.8 ± 7.4 | .38 | 166.2 ± 7.2 | 166.3 ± 6.9 | .76 |
| BMI, kg/m2 | 29.7 ± 4 | 30.5 ± 3.6 | .32 | 27.4 ± 5 | 27 ± 5 | .46 |
| Waist circumference, cm | 97.8 ± 13.8 | 100.2 ± 9.7 | .6 | 83.4 ± 11.5 | 82 ± 11.5 | .67 |
| Symptom duration before diagnosis, y | 3.8 ± 2.7 | 5.4 ± 7.1 | ||||
| Pituitary tumor size (micro/macro) | 3/7 | 3/10 | ||||
| Hormone replacement | GC (2), T4 (2) | GC (1), T4 (1), T (1) | ||||
| Gonadal function | H (3), Eu (7) | Eu (10) | PM (4), H (1), Eu (8) | PM (5), Eu (8) | ||
| Hypertension | 4 | 3 | 4 | 2 | ||
| Diabetes mellitus | 1 | |||||
| Sleep apnea | 6 | 1 | 5 | 1 | ||
| Lipid lowering drugs | 1 | 1 | 1 | 1 | ||
| IGF-I, ng/mLb | 719 ± 171 | 266 ± 146 | .002 | 707 ± 189 | 234 ± 56 | .01 |
| IGF-I, % ULN | 238 ± 52 | −18 ± 43 | <.0001 | 270 ± 70 | −17 ± 26 | <.0001 |
| GH fasting, μg/L | 23 ± 32 | 2 ± 0.54 | .002 | 32 ± 64 | 1.3 ± 1.5 | .01 |
| GH nadir OGTT, μg/L | 19 ± 23 | 0.85 ± 2 | .002 | 23 ± 43 | 0.58 ± 0.38 | .01 |
| Fasting plasma glucose, mg/dL | 92 ± 8.9 | 82 ± 8.9 | .04 | 91 ± 11.5 | 84 ± 10 | .04 |
| HOMA-IR scorec | 4.2 ± 2.6 | 1.75 ± 1.4 | .004 | 3.03 ± 2.6 | 0.72 ± 0.41 | .01 |
| Comp ISId | 3.1 ± 1.9 | 9.2 ± 7 | .01 | 4.8 ± 3.5 | 11.4 ± 6.4 | .002 |
| CRP, mg/L | 0.32 ± 0.06 | 1.69 ± 2.1 | .023 | 0.71 ± 0.95 | 0.53 ± 0.42 | .21 |
| HCY, μmol/L | 7.8 ± 1.9 | 10.5 ± 2.7 | .07 | 9.8 ± 8.7 | 7.9 ± 2.4 | .09 |
| Leptin, ng/mL | 5.7 ± 4.0 | 8.3 ± 5.4 | .19 | 21 ± 23 | 32 ± 24 | .03 |
Abbreviations: BMI, body mass index; Comp ISI, composite insulin sensitivity index; Eu, eugonadal; GC, oral glucocorticoid replacement therapy; H, hypogonadal with no replacement therapy; HOMA-IR, homeostasis model assessment of insulin resistance; PM, postmenopausal, no hormone replacement therapy; T, testosterone replacement therapy; T4, thyroxine replacement therapy; ULN upper limit of normal. Data are means ± SD (range) or number of subjects.
Postoperative data are only from 1 year postoperatively to simplify data presentation and in general did not differ from those at 6 months and 2 years.
Normal IGF-I ranges: age 19, 141–483 ng/mL; age 20, 127–424 ng/mL; ages 21–25 116–358 ng/mL; ages 26–30, 117–329 ng/mL; ages 31–35, 115–307 ng/mL; ages 36–40, 109–284 ng/mL; ages 41–45, 101–267 ng/mL; ages 46–50, 94–252 ng/mL; ages 51–55, 87–238 ng/mL; ages 56–60, 81–225 ng/mL; ages 61–65, 75–212 ng/mL; and ages 66–70, 69–200 ng/mL.
HOMA-IR scores = [fasting serum insulin (microunits per milliliter) × fasting plasma glucose (millimoles per liter)/22.5).
Comp ISI = [10 000/square root of (fasting glucose in milligrams per deciliter × fasting insulin in microunits per milliliter) × (mean glucose × mean insulin OGTT)].